Eskazan Tugce, Saribas Suat, Kocazeybek Bekir
Department of Internal Medicine, İstanbul University Cerrahpaşa Faculty of Medicine, İstanbul 34640, Türkiye.
Department of Medical Microbiology, Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Istanbul 34098, Türkiye.
World J Gastroenterol. 2025 May 7;31(17):104651. doi: 10.3748/wjg.v31.i17.104651.
Advanced gastric cancer (GC) remains a high-mortality malignancy despite progress in diagnosis and treatment, including immunotherapy. Reliable prognostic markers are essential for better patient stratification. The triglyceride-glucose (TyG) index, a marker of insulin resistance, has shown promise in various cancers, but its role in GC remains unclear. Yao investigated its prognostic value in 300 patients with advanced GC receiving immunotherapy and chemotherapy. Their model, which integrates the TyG index, programmed death-ligand 1 expression, and Eastern Cooperative Oncology Group performance status, underscores the impact of metabolic dysfunction on immune response and treatment efficacy. This letter examines the TyG index's potential as a prognostic tool in GC and its implications for treatment strategies guided by metabolic and immune factors, as demonstrated in Yao et al research.
尽管在包括免疫疗法在内的诊断和治疗方面取得了进展，但晚期胃癌（GC）仍然是一种高死亡率的恶性肿瘤。可靠的预后标志物对于更好地对患者进行分层至关重要。甘油三酯-葡萄糖（TyG）指数是胰岛素抵抗的标志物，已在多种癌症中显示出前景，但其在胃癌中的作用仍不清楚。姚研究了其在300例接受免疫疗法和化疗的晚期胃癌患者中的预后价值。他们的模型整合了TyG指数、程序性死亡配体1表达和东部肿瘤协作组体能状态，强调了代谢功能障碍对免疫反应和治疗效果的影响。如姚等人的研究所证明的，这封信探讨了TyG指数作为胃癌预后工具的潜力及其对以代谢和免疫因素为指导的治疗策略的影响。
